ReviewDiscover oncology2026
The crosstalk between epigenetics and metabolism in the malignant cell.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic-epigenetic coupling is recognized as a central hallmark of malignant transformation, characterized by dynamic interplay between cellular metabolism and epigenetic regulation. Cancer cells undergo metabolic reprogramming to meet new demands due to increased biosynthesis and shifted bioenergetics. These changes are responsible for the production of metabolites that are used as substrates or cofactors for key enzymes involved in epigenetic regulation. Thereby, the chromatin structure and gene expression suffer critical changes. Epigenetic modifications including DNA methylation, histone acetylation or non-coding RNA activity, are regulating the transcription of metabolic genes, reshaping the tumor metabolic phenotype. The bidirectional crosstalk between epigenetics and metabolism drives key cancer hallmarks such as proliferation, immune evasion, and drug resistance. Recent discoveries in multi-omics, single-cell sequencing and spatial transcriptomics have opened a new era of high-resolution mapping of metabolic and epigenetic alterations, revealing the high heterogeneity in tumor cells and highlight novel therapeutic targets. In this review we aim to summarize the latest approaches in technological advances in integrated metabolomics and epigenomics, to highlight the critical crosstalk between metabolism and epigenetic changes, and to underscore the need of a deep understanding of these interactions for integrating the multi-omics approach in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.